Melatonin reduces renal interstitial inflammation and improves hypertension in spontaneously hypertensive rats

American Journal of Physiology - Renal Physiology

Volumn 284, Issue 3 53-3, 2003, Pages

  Nava, Mayerly ^a   Quiroz, Yasmir ^a   Vaziri, Nosratola ^b   Rodríguez Iturbe, Bernardo ^a,c  

^a UNIVERSIDAD DEL ZULIA   (Venezuela)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NONE   (Venezuela)

Author keywords

Angiotensin II; Immune infiltration; Interstitial nephritis; Nuclear factor B; Oxidative stress; Salt sensitive hypertension

Indexed keywords

ANGIOTENSIN; ANTIOXIDANT; DRINKING WATER; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MALONALDEHYDE; MELATONIN; PROTEIN SUBUNIT; SUPEROXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DISEASE SEVERITY; DNA BINDING; HYPERTENSION; INTERSTITIAL NEPHRITIS; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT;

EID: 0037369404     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00264.2002     Document Type: Article

References (59)

1. Aebi HE. Catalase. In: Methods in Enzymatic Analysis (3rd ed.), edited by Bergmeyer HU. Weinheim, Germany: Verlag Chemie, 1992, vol. III, p. 271-282.
2. Alvarez V, Quiroz Y, Nava M, Pons H, and Rodríguez-Iturbe B. Overload proteinuria is followed by salt-sensitive hypertension caused by renal infiltration of immune cells. Am J Physiol Renal Physiol 283: F1132-F1141, 2002.
3. Barnes PJ and Kahin M. Nuclear factor-κB. A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336:1066-1071, 1997.
4. Berry C, Brosnan MJ, Fennell J, Hamilton CA, and Dominiczak AF. Oxidative stress and vascular damage in hypertension. Curr Opin Nephrol Hypertens 10: 247-255, 2001.
5. Beutler E, Duron O, and Mikus B. Improved method for the determination of blood glutathione. J Lab Clin Med 16: 882-888, 1963.
6. Beyer CE, Steketee JD, and Saphier D. Antioxidant properties of melatonin - an emerging mystery. Biochem Pharmacol 56: 1265-1272, 1998.
7. Briggs RT, Robinson JM, Karnovsky ML, and Karnovsky MJ. Superoxide production by polymorphonuclear leukocytes. A cytochemical approach. Histochemistry 84: 371-378, 1986.
8. Brzezinski A. Melatonin in humans. N Engl J Med 336: 1186-1195, 1997.
9. Carr A and Frei B. The role of natural antioxidants in preserving the biological activity of endothelium-derived nitric oxide. Free Radic Biol Med 28: 1806-1814, 2000.
10. Contastinescu CS, Hilliard H, Ventura E, and Rostami A. Luzindole, a melatonin receptor antagonist, suppresses experimental autoimmune encephalomyelitis. Pathobiology 65: 190-194, 1997.
11. Dhalla NS, Temsah RM, and Netticadan T. Role of oxidative stress in cardiovascular diseases. J Hypertens 18: 655-673, 2000.
12. Dugo L, Serraino I, Fulia F, De Sarro A, Caputi AP, and Cuzzocrea S. Effect of melatonin on cellular energy depletion mediated by peroxynitrite and poly (ADP-ribose) synthetase activation in an acute model of inflammation. J Pineal Res 31: 76-84, 2001.
13. Garcia-Maurino S, Pozo D, Carrillo-Vico A, Calvo JR, and Guerrero JM. Melatonin activates Th1 lymphocytes by increasing IL-12 production. Life Sci 65: 2143-2150, 1999.
14. Gilad E, Wong HR, Zingarelli B, Virag L, O'Connor M, Salzman AL, and Szabo C. Melatonin inhibits expression of the inducible isoform of nitric oxide synthase in murine macrophages: role of inhibition of NF-κB activation. FASEB J 12: 685-693, 1998.
15. Gitto E, Karbownik M, Reiter RJ, Tan DX, Cuzzocrea S, Chiurazzi P, Cordaro S, Corona G, Trimarchi G, and Barbieri I. Effects of melatonin treatment in septic newborns. Pediatr Res 50: 757-760, 2001.
16. Guerrero JM and Reiter RJ. Melatonin-immune system relationships. Curr Top Med Chem 2: 167-179, 2002.
17. Guijarro C and Egido J. Transcription factor-κB (NF-κB) and renal disease. Kidney Int 59: 415-424, 2001.
18. Herrera J, Nava M, Romero F, and Rodriguez-Iturbe B. Melatonin prevents oxidative stress from iron and erytropoietin administration. Am J Kidney Dis 37: 750-757, 2001.
19. Huether G. Melatonin synthesis in the gastrointestinal tract and the impact of nutritional factors on circulating melatonin. Ann NY Acad Med 719: 146-158, 1994.
20. Johnson RJ, Herrera-Acosta J, Schreiner G, and Rodríguez-Iturbe B. Subtle acquired renal injury as mechanism of salt-sensitive hypertension. N Engl J Med 346: 913-923, 2002.
21. Kawashima K, Miwa Y, Fujimoto K, Oohata H, Nishino H, and Kolke H. Antihypertensive action of melatonin in the spontaneously hypertensive rat. Clin Exp Hypertens 9: 1121-1131, 1987.
22. Kawashima K, Nagakura A, Wurzburger RJ, and Spector S. Melatonin in serum and the pineal of spontaneously hypertensive rats. Clin Exp Hypertens 6: 1517-1528, 1984.
23. Kitiyaka C and Wilcox CS. Antioxidants and hypertension. Curr Opin Nephrol Hypertens 7: 531-538, 1998.
24. K-Laflamme A, Wu L, Foucart S, and de Champlain J. Impaired basal sympathetic tone and alpha 1-adrenergic responsiveness in association with the hypotensive effect of melatonin in spontaneously hypertensive rats. Am J Hypertens 11: 219-229, 1998.
25. Kuhlwein E and Irwin M. Melatonin modulation of lymphocyte proliferation and Th1/Th2 cytokine expression. J Neuroimmunol 117: 51-57, 2001.
26. Lissoni P, Rovelli F, Meregali S, Fumagalli L, Musco F, Brivio F, Brivio O, and Esposti G. Melatonin as a new possible anti-inflammatory agent. J Biol Regul Homeost Agents 11: 157-159, 1997.
27. Makino A, Skelton MM, Zou AP, Roman RJ, and Cowley AW Jr. Increased renal medullary oxidative stress produces hypertension. Hypertension 39: 667-672, 2002.
28. Martins E Jr., Ligeiro de Oliveira AP, Fialho de Araujo AM, Tavares de Lima W, Cipolla-Neto J, and Costa Rosa LF. Melatonin modulates allergic lung inflammation. J Pineal Res 31: 363-369, 2001.
29. Mohan N, Sadeghi K, Reiter RJ, and Meltz ML. The neurohormone melatonin inhibits cytokine, mitogen and ionizing radiation induced NF-κB. Biochem Mol Biol Int 37: 1063-1070, 1995.
30. Nava M, Romero F, Quiroz Y, Parra G, Bonet L, and Rodríguez-Iturbe B. Melatonin attenuates the acute renal failure and the oxidative stress induced by mercuric chloride in rats. Am J Physiol Renal Physiol 279: F910-F918, 2000.
31. Nishiyama A, Seth DM, and Navar LG. Renal interstitial fluid concentrations of angiotensin I and II in anesthetized rats. Hypertension 39: 129-134, 2002.
32. Ohkawa H, Ohishi N, and Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Ann Biochem 95: 351-359, 1979.
33. Pichler R, Franceschini N, Young BA, Hugo C, Andoh TF, Burdman EA, Shankland S, Alpers CE, Bennet WM, Couser WG, and Johnson RJ. Pathogenesis of cyclosporine nephropathy: roles for angiotensin II and osteopontin. J Am Soc Nephrol 6: 1186-1196, 1995.
34. Poeggeler B, Saarela S, Reiter RJ, Tan DX, Chen LD, Manchester LC, and Barlow-Walden LR. Melatonin-a highly potent endogenous radical scavenger and electron donor: new aspects of the oxidation chemistry of this indole accessed in vitro. Ann NY Acad Sci 17: 419-420, 1994.
35. Post A, Holsboer F, and Behl C. Induction of NF-κB activity during haloperidol-induced oxidative toxicity in clonal hippocampal cells: suppression of NF-κB and neuroprotection by antioxidants. J Neurosci 18: 8236-8246, 1998.
36. Quiroz Y, Pons H, Gordon KL, Rincón J, Chávez M, Parra G, Herrera-Acosta J, Gómez-Garre D, Largo R, Egido J, Johnson RJ, and Rodriguez-Iturbe B. Mycophenolate mofetil prevents the salt-sensitive hypertension resulting from short-term nitric oxide synthesis inhibition. Am J Physiol Renal Physiol 281: F38-F47, 2001.
37. Raghavendra V, Singh V, Kulkarni SK, and Agrewala JN. Melatonin enhances Th2 cell mediated immune responses: lack of sensitivity to reversal by naltrexone or benzodiazepine receptor antagonists. Mol Cell Biochem 221: 57-63, 2001.
38. Raij L, Azar S, and Keane W. Mesangial immune injury, hypertension and progressive damage in Dahl rats. Kidney Int 26: 137-143, 1984.
39. Rathaus M and Bernheim J. Oxygen species in the microvascular environment: regulation of vascular tone and the development of hypertension. Nephrol Dial Transplant 17: 216-221, 2002.
40. Reiter RJ, Tan DX, Osuna C, and Gitto E. Actions of melatonin in the reduction of oxidative stress. A review. J Biomed Sci 7:444-458, 2000.
41. Rincón J, Parra G, Quiroz Y, Benatuil L, and Rodríguez-Iturbe B. Cyclosporine A reduces the expression of adhesion molecules in the kidney of rats with chronic serum sickness. Clin Exp Immunol 121: 391-398, 2000.
42. Rodríguez-Iturbe B, Pons H, Herrera-Acosta J, and Johnson RJ. The role of immnnocompetent cells in non-immune renal diseases. Kidney Int 59: 1626-1640, 2001.
43. Rodríguez-Iturbe B, Pons H, Quiroz Y, Gordon K, Rincón J, Chávez M, Parra G, Herrera-Acosta J, Gomez-Garre D, Largo R, Egido J, and Johnson RJ. Mycophenolate mofetil prevents salt-sensitive hypertension resulting from angiotensin II exposure. Kidney Int 59: 2222-2232, 2001.
44. Rodríguez-Iturbe B, Quiroz Y, Herrera-Acosta J, Johnson RJ, and Pons HA. The role of immune cells infiltrating the kidney in the pathogenesis of salt-sensitive hypertension. J Hypertens 20, Suppl 3: S1-S7, 2002.
45. Rodriguez-Iturbe B, Quiroz Y, Nava M, Bonet L, Chavez M, Herrera-Acosta J, Johnson RJ, and Pons HA. Reduction of renal immune cell infiltration results in blood pressure control in genetically hypertensive rats. Am J Physiol Renal Physiol 282: F191-F201, 2002.
46. Ruiz-Ortega M, Lorenzo O, Rupérez M, Esteban V, Mezzano S, and Egido J. Renin angiotensin system and renal damage: emerging data on angiotensin II as a proinflammatory mediator. Contrib Nephrol 135: 123-137, 2001.
47. Schnackenberg CG. Physiological and pathophysiological roles of oxygen radicals in the renal microvasculature. Am J Physiol Regul Integr Comp Physiol 282: R335-R342, 2002.
48. Schreck R, Rieber P, and Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-κB transcription factor and HIV. EMBO J 10: 2247-2258, 1991.
49. Sewerynek E. Melatonin and the cardiovascular system. Neuroendocrinol Lett 23, Suppl 1: 79-83, 2002.
50. Shida CS, Castrucci AM, and Lamy-Freund MT. High melatonin solubility in aqueous medium. J Pineal Res 16: 198-201, 1994.
51. Skwarlo-Sonta K. Melatonin in immunity: comparative aspects. Neuroendocrinol Lett 23, Suppl 1: 61-66, 2002.
52. Svendsen UG. Evidence for an initial, thymus independent and a chronic, thymus dependent phase of DOCA and salt hypertension in mice. Acta Pathol Microbiol Scand 84: 523-528, 1976.
53. Vaziri ND, Wang XQ, Oveisi F, and Rad B. Induction of oxidative stress by glutathione depletion causes severe hypertension in normal rats. Hypertension 36: 142-146, 2000.
54. Vaziri ND, Zhemin N, Oveisi F, and Trnavsky-Hobbs DL. Effect of antioxidant therapy on blood pressure and NO synthase expression in hypertensive rats. Hypertension 36: 957-964, 2000.
55. Velasco-Plaza A, G-Granda T, and Cachero MT. Circadian rhythms of food and water intake and urine excretion in diabetic rats. Physiol Behav 54: 665-670, 1993.
56. Wilcox CS. Reactive oxygen species: roles in blood pressure and kidney function. Curr Hypertens Rep 4: 160-166, 2002.
57. Wilcox CS and Welch WJ. Oxidative stress: cause or consequence of hypertension. Exp Biol Med 226: 619-620, 2001.
58. Zalba G, Beaumont J, San Jose G, Fortuno A, Fortuno MA, and Diez J. Vascular oxidant stress: molecular mechanisms and pathophysiological implications. J Physiol Biochem 56: 57-64, 2000.
59. Zhou XJ, Vaziri ND, Wang XQ, Silva FG, and Laszik Z. Nitric oxide synthase expression in hypertension induced by inhibition of glutathione synthase. J Pharmacol Exp Ther 300: 762-767, 2002.